Brief: Effector Therapeutics Completes Enrollment In Second Of Three Cohorts Of Phase 1B Clinical Trial Of Zotatifin For The Treatment Of Covid-19
Oct 26 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR THERAPEUTICS COMPLETES ENROLLMENT IN SECOND OF
THREE
COHORTS OF PHASE 1B CLINICAL TRIAL OF ZOTATIFIN FOR THE
TREATMENT OF COVID-19
Source text for Eikon: ID:nGNX2kJQ5F
Further company coverage: EFTR.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Effector Therapeutics
See all newsBrief: Effector Therapeutics Expects To Incur One-Time Charges And Cash Expenditures
Brief: Effector Therapeutics Announces It Will Wind Down Operations
Brief: Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
eFFECTOR Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: eFFECTOR Therapeutics Enters Into An At The Market Offering Agreement With H.C. Wainwright